Indivior Welcomes Tony Kingsley to its Board as Non-Executive Director

Indivior Welcomes Tony Kingsley as a New Board Member

Indivior PLC, the renowned global pharmaceutical company, has made a significant addition to its leadership team by appointing Tony Kingsley as an Independent Non-Executive Director. This strategic move, which takes effect on July 1, 2025, is a testament to Indivior's commitment to enhancing its efforts in the treatment of opioid use disorder (OUD).

Tony Kingsley brings with him a wealth of experience and expertise from the biopharmaceutical sector. His impressive career has seen him hold leadership positions in various organizations, where he has been instrumental in driving growth and innovation across multiple scientific fields. This makes him an ideal fit for Indivior's mission of delivering life-transforming treatments to patients battling OUD.

The announcement of Mr. Kingsley’s appointment comes as part of Indivior's relationship agreement with Oaktree Capital Management, L.P., which has supported his addition to the board. David Wheadon, M.D., Chair of the Board at Indivior, expressed his enthusiasm for Kingsley’s appointment, emphasizing the value of his strategic vision and operational prowess. Wheadon stated, “Tony’s significant commercial and clinical development experience will be invaluable to Indivior as we work to realize the full potential of SUBLOCADE® and deliver value to all Indivior stakeholders.”

Kingsley, who is currently the CEO and Director of Stablix, Inc., a biotechnology company pioneering innovative therapies, previously served as President and CEO of Scholar Rock. His leadership at Scholar Rock focused on treating serious diseases associated with protein growth factors. Furthermore, he played a pivotal role at TARIS Bio, navigating the firm through its acquisition by Janssen Pharmaceuticals in 2019. His prior experience as President and Chief Operating Officer at The Medicines Company and as Executive Vice President of Global Commercial Operations at Biogen further solidifies his credentials within the biopharmaceutical industry.

In addition to his extensive industry experience, Kingsley holds a magna cum laude degree from Dartmouth College and an M.B.A. from the prestigious Harvard Business School. His academic background, coupled with his professional achievements, positions him to make a significant contribution to Indivior as the company continues its vital work in addressing the opioid crisis.

Kingsley voiced his commitment to Indivior's mission, stating, “Indivior has a long and successful track record of addressing the opioid use disorder with its portfolio of medicines to make meaningful recovery possible. I look forward to working closely with the Board and management team to advance Indivior's mission and strengthen its position as a leader in delivering life-transforming treatments for opioid use disorder.”

Indivior is recognized globally for its dedication to transforming OUD into a manageable chronic disease through evidence-based treatments. The firm is proud of its achievements and its extensive portfolio of medicines that have helped countless individuals on the recovery path. With Kingsley now on board, the company is poised to enhance its strategic initiatives and expand its offerings to even more patients worldwide.

About Indivior

Headquartered in Richmond, Virginia, Indivior is committed to delivering solutions for opioid use disorder. With operations spanning over 30 countries and a team of more than 1,000 professionals, Indivior aims to change lives through its drug development strategies and innovative approaches in healthcare. To learn more about Indivior's mission and vision, visit Indivior's official website or connect on LinkedIn.